ABVX
Abivax - ADR

1,385
Loading...
Loading...
News
all
press releases
Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results — Retail Buzz Builds Around Blockbuster Potential
The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.
Stocktwits·2mo ago
News Placeholder
More News
News Placeholder
US-listed Abivax shares skyrocket on positive phase 3 data for colitis drug
Investing.com-- U.S.-listed shares of French biotech firm Abivax SA (EPA:ABVX) (NASDAQ:ABVX) skyrocketed in post-market trading on Tuesday after the company reported strong results from late-stage trials of its oral ulcerative colitis treatment, obefazimod.
investing.com·2mo ago
News Placeholder
Kepler Capital Reaffirms Their Buy Rating on Abivax SA (0RA9)
In a report released on July 16, Justine Telliez from Kepler Capital maintained a Buy rating on Abivax SA (0RA9 Research Report), with a price ta...
TipRanks Financial Blog·1y ago
News Placeholder
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the...
Globe Newswire·1y ago
News Placeholder
Abivax reports 2023 financial results and operational update
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR...
Globe Newswire·1y ago
News Placeholder
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics...
Accesswire·2y ago
News Placeholder
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET Abivax SA (Euronext Paris and Nasdaq: ABVX) ( Abivax or the Company ), a...
Globe Newswire·2y ago
News Placeholder
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December...
Globe Newswire·2y ago
News Placeholder
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024...
Globe Newswire·2y ago

Latest ABVX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.